Chugai Pharmaceutical : Chugai obtains Japanese regulatory approval for Tecentriq for additional indication of alveolar soft part sarcoma, an ultrarare disease

Chugai Pharmaceutical Co., Ltd. announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare for the anti─cancer agent/humanized anti─PD─L1 monoclonal antibody Tecentriq